Literature DB >> 11694406

Thrombotic thrombocytopenic purpura: prospective neurologic, neuroimaging and neurophysiologic evaluation.

G Meloni1, A Proia, G Antonini, C De Lena, V Guerrisi, S Capria, S M Trisolini, G Ferrazza, G Sideri, F Mandelli.   

Abstract

BACKGROUND AND OBJECTIVES: Neurologic symptoms are present in 60% of patients with thrombotic thrombocytopenic purpura (TTP) on initial examination and ultimately develop in about 90% of cases during the course of the disease. Despite central nervous system involvement being frequent, abnormalities in the brain of patients with TTP are infrequent on neuroimaging (CT/MRI) and neurophysiologic (EEG) evaluation, often reversible and mainly limited to symptomatic stages of the disease. The aim of our study was to establish the value of a complete neurologic screening as part of the work up of TTP. DESIGN AND METHODS: We prospectively evaluated 16 TTP patients, performing serial neurologic, neuroimaging and EEG examinations, independently of the presence of an objective central nervous system involvement.
RESULTS: Our study shows that a complete neurologic evaluation is of modest help in improving the diagnosis of TTP, but may be useful for the neurologic management. INTERPRETATION AND
CONCLUSIONS: Accurate neuroimaging and, especially, EEG evaluation and monitoring allowed us to identify patients who could benefit from anticonvulsive therapy, avoiding the unnecessary administration of the latter. The prognostic utility of complete neurologic screening in TTP remains to be conclusively demonstrated in larger prospective neurologic studies.

Entities:  

Mesh:

Year:  2001        PMID: 11694406

Source DB:  PubMed          Journal:  Haematologica        ISSN: 0390-6078            Impact factor:   9.941


  8 in total

1.  A dramatic response to rituximab in a patient with resistant thrombotic thrombocytopenic purpura (TTP) who developed acute stroke.

Authors:  Hakan Ozdogu; Can Boga; Ebru Kizilkilic; Mahmut Yeral; Ilknur Kozanoglu; Mehmet Karatas
Journal:  J Thromb Thrombolysis       Date:  2007-01-13       Impact factor: 2.300

2.  Macrovascular thrombosis in critically ill patients with thrombotic micro-angiopathies.

Authors:  Laurent Camous; Agnès Veyradier; Michael Darmon; Lionel Galicier; Eric Mariotte; Emmanuel Canet; Nathalie Parquet; Élie Azoulay
Journal:  Intern Emerg Med       Date:  2012-10-07       Impact factor: 3.397

3.  Formation and Resolution of Pial Microvascular Thrombosis in a Mouse Model of Thrombotic Thrombocytopenic Purpura.

Authors:  Reheman Adili; Michael Holinstat
Journal:  Arterioscler Thromb Vasc Biol       Date:  2019-07-25       Impact factor: 8.311

Review 4.  Neurologic Complications in the Intensive Care Unit.

Authors:  Clio Rubinos; Sean Ruland
Journal:  Curr Neurol Neurosci Rep       Date:  2016-06       Impact factor: 5.081

5.  Unfavorable course in pregnancy-associated thrombotic thrombocytopenic purpura necessitating a perimortem Cesarean section: a case report.

Authors:  Ernesto González-Mesa; Isidoro Narbona; Marta Blasco; Isaac Cohen
Journal:  J Med Case Rep       Date:  2013-04-29

6.  Tacrolimus associated thrombotic thrombocytopenic purpura (TTP) and stroke in the young.

Authors:  Boby Varkey Maramattom; Rahul Patil; Punnoose Thomas; Binu Upendran
Journal:  Ann Indian Acad Neurol       Date:  2015 Jan-Mar       Impact factor: 1.383

7.  Thrombotic thrombocytopenic purpura with concomitant small- and large-vessel thrombosis, atypical posterior reversible encephalopathy syndrome and cerebral microbleeds.

Authors:  Wong Li Yu; Thomas Leung; Yannie Soo; Jessamyn Lee; Ka Sing Wong
Journal:  Oxf Med Case Reports       Date:  2015-02-03

8.  Treatment of Acute Kidney Injury in Hemolythic Uremic Syndrome (TTP).

Authors:  Aida Coric; Halima Resic; Selma Ajanovic; Nejra Prohic; Amela Beciragic
Journal:  Med Arch       Date:  2018-12
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.